Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Non-Current Liabilities (2018 - 2025)

Summit Therapeutics' Total Non-Current Liabilities history spans 8 years, with the latest figure at $67.6 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities rose 6.99% year-over-year to $67.6 million; the TTM value through Sep 2025 reached $67.6 million, up 6.99%, while the annual FY2024 figure was $45.2 million, 63.47% down from the prior year.
  • Total Non-Current Liabilities reached $67.6 million in Q3 2025 per SMMT's latest filing, up from $62.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $536.1 million in Q4 2022 to a low of $19.7 million in Q3 2022.
  • Average Total Non-Current Liabilities over 5 years is $96.0 million, with a median of $63.2 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: surged 1862.67% in 2022, then tumbled 76.93% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $27.3 million in 2021, then soared by 1862.67% to $536.1 million in 2022, then plummeted by 76.93% to $123.7 million in 2023, then crashed by 63.47% to $45.2 million in 2024, then soared by 49.7% to $67.6 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Total Non-Current Liabilities are $67.6 million (Q3 2025), $62.8 million (Q2 2025), and $37.8 million (Q1 2025).